ASA-ILD measurement algorithm.

ASA-ILD measurement algorithm.

<p>Abbreviations: ASA-ILD, algorithm for self-assessment in interstitial lung diseases.</p>

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Ekaterina Krauss (6417968) (author)
مؤلفون آخرون:	Laurenz H. Claas (20636655) (author), Silke Tello (20636658) (author), Jennifer Naumann (8739921) (author), Sandra Wobisch (20636661) (author), Stefan Kuhn (1363071) (author), Raphael W. Majeed (20636664) (author), Karen Moor (20636667) (author), Maria Molina-Molina (417753) (author), Oisin Byrne (20636670) (author), Rebecca Borton (16742595) (author), Marlies S. Wijsenbeek (11229228) (author), Nik Hirani (342996) (author), Carlo Vancheri (202860) (author), Bruno Crestani (288325) (author), Andreas Guenther (33941) (author)
منشور في:	2025
الموضوعات:	Medicine Pharmacology Biotechnology Cancer Science Policy Infectious Diseases Biological Sciences not elsewhere classified Information Systems not elsewhere classified reported outcome measures recent &# 160 progressive pulmonary fibrosis interstitial lung diseases artificial intelligence software usa ), along ppf ), remains oxygen saturation measurements clinical trials register app protocol developed eurildreg principal investigators providing automated feedback exercise testing within conducted strictly according analyze spirometry maneuvers ild ), developed improve early detection multicenter eurildreg study ild )</ p early detection italy ), patientmpower app handheld clinical centered measurements safer detection ild progression ild algorithm xlink "> usage instructions symptom burden stand test spirobank smart smartphone applications send reminders respiratory infections registry upon pulse oximeter patientmpower ltd patientmpower account nonin medical minute sit led monitoring lcq ). informed consent includes questionnaires home monitoring holds promise health technologies grade spirometer ethics committee eq5d vas ensuring compliance disease progression clinician involvement ats criteria acute exacerbations 1stst ).
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

Adherence rates for spirometry and the one-minute sit-to-stand test in the non-adherent cohort (pilot study).
حسب: Ekaterina Krauss (6417968)
منشور في: (2025)

Adherence rates for spirometry and the one-minute sit-to-stand test in the adherent cohort (pilot study).
حسب: Ekaterina Krauss (6417968)
منشور في: (2025)

References list Imaging biomarker in ILD
حسب: Dr. Pradosh Kumar Sarangi (21492002)
منشور في: (2025)

Table 1_Circulating extracellular vesicles as predictive biomarkers of progressive interstitial lung disease in systemic sclerosis—a prospective cohort study.docx
حسب: J. Colic (21216464)
منشور في: (2025)

Supplementary file 1_Polydatin-curcumin formulation alleviates CTD-ILD-like lung injury in mice via GABBR/PI3K/AKT/TGF-β pathway.docx
حسب: Zhengju Zhang (12253994)
منشور في: (2025)

Clinical efficacy and safety evaluation of drug therapies for the treatment of progressive fibrotic-interstitial lung diseases (PF-ILDs): a network meta-analysis of randomized controlled trials
حسب: Pooja Singh (608019)
منشور في: (2025)

Data Sheet 1_Characterization of sarcoidosis at a combined rheumatology-pulmonary clinic.docx
حسب: Megan Schermerhorn (22246129)
منشور في: (2025)

Data Sheet 1_Exhaustion of NK cells and interferon activation in anti-MDA5+ dermatomyositis are associated and determine the development of ILD.docx
حسب: Chenyi Shao (6444911)
منشور في: (2025)

Data Sheet 1_Toll interacting protein gene polymorphisms in patients with systemic sclerosis: association with interstitial lung disease, outcome, and survival.docx
حسب: Niels Schröder (21404615)
منشور في: (2025)

Presentation 1_Case report: Exploring efficacy of tofacitinib in modulating interferon response in five case of anti-MDA5+ dermatomyositis with interstitial lung disease.pdf
حسب: Jie Zhao (49409)
منشور في: (2025)

Table 1_Clinical features and recurrence risk prediction model in patients with idiopathic inflammatory myopathies-associated interstitial lung disease: a retrospective study from Ningbo.doc
حسب: Di Wu (23906)
منشور في: (2025)

Fred_Severo_etal datasets
حسب: Frederico Severo (22113424)
منشور في: (2025)

Data Sheet 2_Myeloid PDLIM2 repression as a common mechanism of infection susceptibility in lung diseases.csv
حسب: Feng Gao (3548)
منشور في: (2025)

Data Sheet 1_Myeloid PDLIM2 repression as a common mechanism of infection susceptibility in lung diseases.pdf
حسب: Feng Gao (3548)
منشور في: (2025)

Table 1_Case report: Pulmonary non-Langerhans cell histiocytosis in a dog with acute interstitial granulomatous pneumonia.docx
حسب: Kyle L. Granger (20554869)
منشور في: (2025)

Table 2_Case report: Pulmonary non-Langerhans cell histiocytosis in a dog with acute interstitial granulomatous pneumonia.docx
حسب: Kyle L. Granger (20554869)
منشور في: (2025)

Image 1_Case report: Pulmonary non-Langerhans cell histiocytosis in a dog with acute interstitial granulomatous pneumonia.tiff
حسب: Kyle L. Granger (20554869)
منشور في: (2025)

Hazard ratios (HR) for all-cause mortality with 95% confidence intervals from Cox regression models using the 2005 vs. the 2022 guidelines for grading severity, normal FVC (<i>n</i> = 5,238) and normal TLCO (<i>n</i> = 3,704) as reference for lung function severity, sarcoidosis as reference for other diagnosis groups.
حسب: Piotr W. Boros (21446186)
منشور في: (2025)

Kaplan–Meier estimation in groups of patients recategorized according to 2022 ATS/ERS guidelines with comparison to those with concordant classification for FEV<sub>1</sub>, FVC, TLC and TLCO (first part of name is grade according to 2005 or 1991 classification based on % pred., the second is from ATS/ERS 2022 based on <i>z</i>-scores, results for recategorized patients are shaded).
حسب: Piotr W. Boros (21446186)
منشور في: (2025)

Characteristics of patients with abnormal lung function whose severity classification changed when the <i>z</i>-score guidelines from 2022 were applied in comparison to those who were not reclassified and stayed in 2005 category.
حسب: Piotr W. Boros (21446186)
منشور في: (2025)

Study group characteristics with the breakdown of the data for each diagnosis group.
حسب: Piotr W. Boros (21446186)
منشور في: (2025)

Categorization of lung function impairment severity recommended by ATS/ERS 2022 [4] and previously in 2005 [3] and ATS 1991 [17] guidelines.
حسب: Piotr W. Boros (21446186)
منشور في: (2025)

Cox proportional hazards model for severity of FVC (left panel) and TLCO (right panel) levels.
حسب: Piotr W. Boros (21446186)
منشور في: (2025)

Kaplan–Meier analyses for survival according to 2005 and 1991 vs. 2022 guidelines for FEV<sub>1</sub> (upper left), FVC (upper right), TLC (lower left) and TLCO (lower right) severity.
حسب: Piotr W. Boros (21446186)
منشور في: (2025)

Plots of FEV<sub>1</sub> (upper left), FVC (upper right), TLC (lower left) and TLCO (lower right) values expressed in % pred. (<i>y</i>-axis) against <i>z</i>-scores (<i>x</i>-axis) with subjects stratified by age group.
حسب: Piotr W. Boros (21446186)
منشور في: (2025)

Assessment of alveolar capillary membrane permeability using technetium 99 m-diethylene triamine pentaacetate (Tc99m–DTPA) aerosols in patients with diffuse cutaneous systemic sclerosis – a cross-sectional study
حسب: Muniza Bai (22829528)
منشور في: (2025)

List of transcripts analyzed for differential expression between ILD subtypes and with lung function.
حسب: Daniel He (3477920)
منشور في: (2024)

Summary table of clinical and demographic characteristics of patients with ILD profiled for lung ISH. Data for race, DLCO%, and treatment status was not available.
حسب: Daniel He (3477920)
منشور في: (2024)

Histological staining of tissue microarray cores taken from donor lungs of patients with idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis (HP), and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
حسب: Daniel He (3477920)
منشور في: (2024)

Table_1_ILDIM-MFAM: interstitial lung disease identification model with multi-modal fusion attention mechanism.XLSX
حسب: Bin Zhong (3336852)
منشور في: (2024)

Table_2_ILDIM-MFAM: interstitial lung disease identification model with multi-modal fusion attention mechanism.XLSX
حسب: Bin Zhong (3336852)
منشور في: (2024)

Expression of <i>KLRF1</i>, <i>LTK</i>, <i>VCAN</i> in whole blood (log<sub>2</sub> RNA expression) or lung tissue microarray sections (H-Score) containing samples from patients with idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis (HP), and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
حسب: Daniel He (3477920)
منشور في: (2024)

Chest CTs of pneumomediastinum found in patients with myositis-associated ILD.
حسب: Junghee Jung (19568095)
منشور في: (2025)

Cox proportional hazard analysis of risk factors for mortality in patients with myositis-associated ILD.
حسب: Junghee Jung (19568095)
منشور في: (2025)

Summary table of clinical demographics of patients probed for whole blood RNA expression.
حسب: Daniel He (3477920)
منشور في: (2024)

Correlation of principal component analysis (PCA) components (PCs) with demographic and clinical metadata.
حسب: Daniel He (3477920)
منشور في: (2024)

Coefficient weights of biomarker panels developed for each between subtype comparison.
حسب: Daniel He (3477920)
منشور في: (2024)

Classification model performance on cross-validation for selected learning algorithms.
حسب: Daniel He (3477920)
منشور في: (2024)

Illustrative image of the CALIPER of a patient with SSc and ILD.
حسب: Fernanda Godinho Amorim (19751349)
منشور في: (2024)

Clinical characteristics of SSc patients according to the presence or absence of interstitial lung disease (ILD) at baseline.
حسب: Fernanda Godinho Amorim (19751349)
منشور في: (2024)

Cannot write session to /tmp/vufind_sessions/sess_n4lvumuhbobsl08s21vrer1b5b